These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34569357)

  • 1. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey.
    Authier S; Brock WJ; Halpern W; Harris SN; Jones D; McGovern T; McGovern PD; Pugsley MK
    Int J Toxicol; 2021 Dec; 40(6):487-505. PubMed ID: 34569357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
    Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA
    Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective.
    Reynolds VL; Butler P; Abernathy MM; Aschenbrenner L; Best DD; Blank J; Crosby M; Custer L; Escobar PA; Kolaja K; Moggs J; Shuey D; Snyder C; Van Vleet T; Zhou J; Hart TK
    Regul Toxicol Pharmacol; 2020 Nov; 117():104746. PubMed ID: 32911461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of emerging safety biomarkers in nonclinical and clinical safety assessment - The current and future state: An IQ DruSafe industry survey.
    Zabka TS; Burkhardt J; Reagan WJ; Gautier JC; Glaab WE; Guffroy M; Harding J; Brees D; McDuffie E; Ramaiah L; Schultze AE; Smith JD; Wolfreys A; Dalmas DA
    Regul Toxicol Pharmacol; 2021 Mar; 120():104857. PubMed ID: 33387566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.
    Piccotti JR; Lebrec HN; Evans E; Herzyk DJ; Hastings KL; Burns-Naas LA; Gourley IS; Wierda D; Kawabata TT
    J Immunotoxicol; 2009 Mar; 6(1):1-10. PubMed ID: 19519157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
    Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
    Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice.
    Namdari R; Jones K; Chuang SS; Van Cruchten S; Dincer Z; Downes N; Mikkelsen LF; Harding J; Jäckel S; Jacobsen B; Kinyamu-Akunda J; Lortie A; Mhedhbi S; Mohr S; Schmitt MW; Prior H
    Regul Toxicol Pharmacol; 2021 Nov; 126():105029. PubMed ID: 34455009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.
    Halpern WG; Ameri M; Bowman CJ; Elwell MR; Mirsky ML; Oliver J; Regan KS; Remick AK; Sutherland VL; Thompson KE; Tremblay C; Yoshida M; Tomlinson L
    Toxicol Pathol; 2016 Aug; 44(6):789-809. PubMed ID: 27235322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benchmarking safety pharmacology regulatory packages and best practice.
    Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
    J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety pharmacology investigations in toxicology studies: an industry survey.
    Authier S; Vargas HM; Curtis MJ; Holbrook M; Pugsley MK
    J Pharmacol Toxicol Methods; 2013; 68(1):44-51. PubMed ID: 23685201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory Forum Opinion Piece
    Morgan SJ; Couch J; Guzzie-Peck P; Keller DA; Kemper R; Otieno MA; Schulingkamp RJ; Jones TW
    Toxicol Pathol; 2017 Apr; 45(3):372-380. PubMed ID: 28351296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methodological innovations expand the safety pharmacology horizon.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Industry Survey With Focus on Cardiovascular Safety Pharmacology Study Design and Data Interpretation.
    Authier S; Abernathy MM; Correll K; Chui RW; Dalton J; Foley CM; Friedrichs GS; Koerner JE; Kallman MJ; Pannirselvam M; Redfern WS; Urmaliya V; Valentin JP; Wisialowski T; Zabka TS; Pugsley MK
    Int J Toxicol; 2020; 39(4):274-293. PubMed ID: 32406289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety pharmacology investigations on the nervous system: An industry survey.
    Authier S; Arezzo J; Delatte MS; Kallman MJ; Markgraf C; Paquette D; Pugsley MK; Ratcliffe S; Redfern WS; Stevens J; Valentin JP; Vargas HM; Curtis MJ
    J Pharmacol Toxicol Methods; 2016; 81():37-46. PubMed ID: 27263834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies.
    McDorman KS; Bennet BM; Colman K; Fikes JD; Keirstead ND; Lanning Retired L; Munch B; Romeike A; Schafer KA; Schorsch F; Thibodeau MS; Thomas HC; Troth S; Vahle JL; Geoly FJ
    Toxicol Pathol; 2024 Feb; 52(2-3):138-148. PubMed ID: 38840532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolites in safety testing.
    Robison TW; Jacobs A
    Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods in safety pharmacology in focus.
    Pugsley MK; Gallacher DJ; Towart R; Authier S; Curtis MJ
    J Pharmacol Toxicol Methods; 2008; 58(2):69-71. PubMed ID: 18707009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices.
    Valentin JP; Guillon JM; Jenkinson S; Kadambi V; Ravikumar P; Roberts S; Rosenbrier-Ribeiro L; Schmidt F; Armstrong D
    J Pharmacol Toxicol Methods; 2018; 93():7-14. PubMed ID: 30030184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.